The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.
Eric Jeffrey Sherman
No relevant relationships to disclose
Alan Loh Ho
Research Funding - Pfizer
Matthew G. Fury
No relevant relationships to disclose
Shrujal S. Baxi
No relevant relationships to disclose
Sofia Haque
No relevant relationships to disclose
Susan H. Korte
No relevant relationships to disclose
Stephanie Smith-Marrone
No relevant relationships to disclose
Han Xiao
No relevant relationships to disclose
Ronald A. Ghossein
No relevant relationships to disclose
James A. Fagin
No relevant relationships to disclose
David G. Pfister
No relevant relationships to disclose